Westfield Capital Management
ALDR

Westfield Capital Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Westfield Capital Management’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-397,350
Closed -$8.27M – 290
2017
Q1 		$8.27M Sell
397,350
-965
-0.2% -$21.4K 0.07% 214
2016
Q4 		$8.29M Sell
398,315
-4,760
-1% -$124K 0.07% 214
2016
Q3 		$13.2M Buy
+403,075
New +$12.3M 0.11% 192

Other funds holding ALDR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Westfield Capital Management's ALDR Position: Q2 2017 in Review

Westfield Capital Management sold out of Alder Biopharmaceuticals (ALDR) in Q2 2017, closing a stake of 397,350 shares — an estimated $8.27M sold.

Westfield Capital Management first reported a position in ALDR in Q3 2016 and held it in 3 quarters. The position peaked at $13.2M in Q3 2016. 128 funds tracked by Wall St. Rank hold ALDR as of Q2 2017.

  • Westfield Capital Management reported no remaining Alder Biopharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Westfield Capital Management sold 397,350 Alder Biopharmaceuticals shares in Q2 2017, an estimated $8.27M.
  • Westfield Capital Management first reported a position in Alder Biopharmaceuticals in Q3 2016 and held it in 3 quarters.
  • Westfield Capital Management's Alder Biopharmaceuticals position peaked at $13.2M in Q3 2016.
  • 128 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q2 2017.

Based on Westfield Capital Management's 13F filing for Q2 2017, filed 11 Aug 2017.